0832 GMT - Bayer's fourth-quarter results came in better than expected, but its 2026 outlook points to cuts to consensus estimates due to foreign-exchange rates, analysts at J.P. Morgan say in a research note. The German agricultural and pharmaceutical group reported quarterly sales that beat consensus estimates by 1%, mainly thanks to its agricultural business, the analysts say. Adjusted earnings beat consensus forecasts by 3%, driven by both pharma and agriculture, they add. Bayer's outlook implies a cut of around 3% to consensus estimates on 2026 adjusted Ebitda, largely related to currencies, according to JPM. Nevertheless, investors seem more focused on the outcome of Bayer's proposed Roundup settlement and the U.S. Supreme Court decision than on results, the analysts say. Shares fall 3.4%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 04, 2026 03:32 ET (08:32 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.